$2.69
4.27% day before yesterday
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US00534A1025
Symbol
IVVD

Adagio Therapeutics Inc Stock price

$2.69
+0.36 15.45% 1M
+1.89 236.71% 6M
+2.25 507.09% YTD
+2.16 407.16% 1Y
+0.99 58.24% 3Y
-14.31 84.18% 5Y
-14.31 84.18% 10Y
-14.31 84.18% 20Y
Nasdaq, Closing price Fri, Dec 26 2025
-0.12 4.27%
ISIN
US00534A1025
Symbol
IVVD
Industry

Key metrics

Basic
Market capitalization
$778.7m
Enterprise Value
$693.8m
Net debt
positive
Cash
$85.0m
Shares outstanding
214.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
15.6 | 15.0
EV/Sales
13.9 | 13.4
EV/FCF
negative
P/B
8.4
Financial Health
Equity Ratio
52.2%
Return on Equity
-251.6%
ROCE
-65.7%
ROIC
-172.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$50.0m | $51.8m
EBITDA
$-61.8m | $-56.9m
EBIT
$-62.2m | $-63.9m
Net Income
$-59.9m | $-88.2m
Free Cash Flow
$-80.4m
Growth (TTM | estimate)
Revenue
332.9% | 103.9%
EBITDA
73.5% | 67.6%
EBIT
73.5% | 63.9%
Net Income
73.4% | 48.1%
Free Cash Flow
58.2%
Margin (TTM | estimate)
Gross
93.3%
EBITDA
-123.4% | -110.0%
EBIT
-124.4%
Net
-119.6% | -170.4%
Free Cash Flow
-160.8%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
12.4%
Employees
100
Rev per Employee
$250.0k
Show more

Is Adagio Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Adagio Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Adagio Therapeutics Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Adagio Therapeutics Inc forecast:

Buy
78%
Hold
22%

Financial data from Adagio Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
50 50
333% 333%
100%
- Direct Costs 3.33 3.33
274% 274%
7%
47 47
338% 338%
93%
- Selling and Administrative Expenses 63 63
2% 2%
125%
- Research and Development Expense 46 46
75% 75%
92%
-62 -62
74% 74%
-123%
- Depreciation and Amortization 0.48 0.48
72% 72%
1%
EBIT (Operating Income) EBIT -62 -62
74% 74%
-124%
Net Profit -60 -60
73% 73%
-120%

In millions USD.

Don't miss a Thing! We will send you all news about Adagio Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adagio Therapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID.
Neutral
GlobeNewsWire
3 days ago
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced initiation of the DECLARATION trial evaluating VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID. DECLARATION is the company's Biologics License Application (BLA)-enabling, Phase 3 randomized, triple-blind, placebo-controlled clinical trial to ...
Neutral
GlobeNewsWire
about one month ago
NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in Miami, FL.
More Adagio Therapeutics Inc News

Company Profile

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Head office United States
CEO William Duke
Employees 100
Founded 2020
Website invivyd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today